Indication
Elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Loading your page…
Loading your page…
Lymphoma
Marketing Authorisation Holder: Stemline Therapeutics B.V.
EMA Authorisation: 07/01/2021
INN: tagraxofusp
AI Drug & Interaction Analysis
Free account required
Ask Osler about Elzonris: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.